BioMap and MGI Sign Strategic Agreement to Build Dedicated Cell Models
On September 11, 2026, BioMap (Beijing) Intelligent Technology and MGI formally signed a strategic cooperation agreement.
The two parties will jointly build dedicated cell models for specific customers and research and development scenarios, with a focus on improving capabilities such as cell-state modeling and perturbation-response prediction.
Using these models as a foundation, the two parties will also build dedicated high-quality data infrastructure for virtual cells and virtual perturbations, and explore integrated product models such as equipment plus models plus agents, in order to accelerate the AI for Science process.
Why this event matters
The event has a measured impact on 4 industrys. The strongest current signal is positive for Artificial Intelligence, with intensity 60/100 and 70% confidence over a medium term horizon.
Artificial Intelligence
- Direction
- positive
- Intensity
- 60
- Confidence
- 70%
- Horizon
- Medium term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 50
- Confidence
- 65%
- Horizon
- Medium term
Biotechnology
- Direction
- positive
- Intensity
- 45
- Confidence
- 60%
- Horizon
- Long term
Medical Equipment
- Direction
- positive
- Intensity
- 40
- Confidence
- 55%
- Horizon
- Long term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.